$144.61
Above FV▼ -35.6% against the close used
Model range $64.89 – $182.80
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Bear$64.89Fair value$144.61Bull$182.80
FairClose
52-week traded range
52W low $114.9852W high $236.75
The 52-week range is measured from the stored price history, not estimated.
Trading above the consensus fair value
National Healthcare, Corp. closed at $224.47, 55.2% above the consensus fair value of $144.61 drawn from 9 valuation models.
Financial DNA score 52/100 — Good. P/E of 29.3x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
DCF Valuation
$182.80
-18.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8.5%, r=10%, tg=3%, n=10yr
Graham Number
$110.54
-50.8%
√(22.5 × EPS × BVPS)
EPS=7.67, BVPS=70.81 · outside Graham range (P/E 29.3, P/B 3.2) — asset-light, treat as a rough floor
P/E Fair Value
$153.40
-31.7%
EPS × 20x (sector P/E)
EPS=7.67, Sector P/E=20x
Peter Lynch (PEG)
$64.89
-71.1%
EPS × Growth% (PEG = 1 is fair)
EPS=7.67, g=8.5%
EV/EBITDA
$157.58
-29.8%
(EBITDA × 14.2x − Net Debt) ÷ Shares
EBITDA=173.27M
Dividend Discount (DDM)
$136.97
-39.0%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=2.54, r=10%, g=8%
Book Value (P/B)
$83.03
-63.0%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=70.81, ROE=10.7%, g=6%, r=10%
Reverse DCF
$224.47
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 12.3% | Historical: 8.5%
Margin of Safety
$111.69
-50.2%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=148.91, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.